Trial Profile

An Open-Label Multicenter Phase 1b Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs H3B-6545 (Primary) ; Palbociclib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions
Sponsors Eisai Inc

Most Recent Events

10 Sep 2024 Planned End Date changed from 31 Aug 2024 to 31 Aug 2025.
04 Jun 2024 Results (At data cutoff (16 Sept 22), n=31 )presented at the 60th Annual Meeting of the American Society of Clinical Oncology
26 Mar 2024 Planned End Date changed from 31 Mar 2024 to 31 Aug 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com